SCHEMBL3725344

SCHEMBL3725344

CCCC=Cc1cc(CC(=O)O)cc(OCc2ccccc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.52
ALDH1A1 P00352 1/20 0.52
PKM P14618 1/20 0.52
LTB4R Q15722 4/20 0.51
LTB4R2 Q9NPC1 4/20 0.51
CYP1A1 P04798 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP19A1 P11511 1/20 0.48
AKR1C3 P42330 2/20 0.47
AKR1C2 P52895 2/20 0.47
PPARA Q07869 2/20 0.46
FFAR1 O14842 1/20 0.46
PPARG P37231 1/20 0.46
PPARD Q03181 1/20 0.46
LMNA P02545 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
RXRA P19793 1/20 0.43
RXRB P28702 1/20 0.43
RXRG P48443 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3725341 1.00 KDM4E (0.52) KDM4EALDH1A1PKMLTB4RLTB4R2
SCHEMBL29424405 0.90 KDM4E (0.49) KDM4EALDH1A1PKMLTB4RLTB4R2
SCHEMBL1628656 0.90 KDM4E (0.49) KDM4EALDH1A1PKMLTB4RLTB4R2
SCHEMBL290302 0.81 KDM4E (0.46) KDM4EALDH1A1PKMCYP1A1CYP1A2
SCHEMBL290303 0.81 KDM4E (0.46) KDM4EALDH1A1PKMCYP1A1CYP1A2
SCHEMBL17678291 0.80 THRB (0.40) KDM4EALDH1A1LTB4RLTB4R2AKR1C3
SCHEMBL9205498 0.79 LTB4R (0.68) LTB4RLTB4R2CYP1A2FFAR1LMNA
SCHEMBL2957881 0.79 MEN1 (0.67) LTB4RLTB4R2CYP1A2FFAR1LMNA
SCHEMBL28424630 0.78 PTGER4 (0.43) KDM4EALDH1A1PKMLTB4RLTB4R2
SCHEMBL289617 0.78 PPARG (0.47) KDM4EALDH1A1PKMLTB4RLTB4R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11185521-B2 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis Liminal Biosciences Limited (GB) 2021-11-30 US disclosed
US-20210085626-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION LIMINAL BIOSCIENCES LTD (GB) 2021-03-25 US disclosed
US-20210002202-A1 Substituted Aromatic Compounds and Pharmaceutical Uses Thereof PROMETIC BIOSCIENCES, INC. (CA) 2021-01-07 US disclosed
US-10869849-B2 Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration Liminal Biosciences Limited (GB) 2020-12-22 US disclosed
EP-3443957-B1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER LIMINAL BIOSCIENCES LTD (GB) 2020-11-25 EP disclosed
US-10815183-B2 Substituted aromatic compounds and pharmaceutical uses thereof PROMETIC PHARMA SMT LIMITED (GB) 2020-10-27 US disclosed
US-20200237693-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS LIMINAL BIOSCIENCES INC (GB) 2020-07-30 US disclosed
US-20200078324-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION Liminal Biosciences Limited (GB) 2020-03-12 US disclosed
US-10450258-B2 Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis PROMETIC PHARMA SMT LIMITED (GB) 2019-10-22 US disclosed
US-10391073-B2 Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration PROMETIC PHARMA SMT LIMITED (GB) 2019-08-27 US disclosed
WO-2016074068-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION PROMETIC BIOSCIENCES INC. (CA) 2016-05-19 WO disclosed
WO-2016054728-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS PROMETIC BIOSCIENCES INC. (CA) 2016-04-14 WO disclosed
EP-2427416-B1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF PROMETIC PHARMA SMT LTD (GB) 2016-03-09 EP disclosed
EP-2970088-A1 SUBSTITUTED AROMATIC COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, LIVER FIBROSIS, SKIN FIBROSIS AND CARDIAC FIBROSIS ProMetic BioSciences Inc. (CA) 2016-01-20 EP disclosed
US-9114118-B2 Compounds and compositions for the treatment of cancer PROMETIC BIOSCIENCES INC. (CA) 2015-08-25 US disclosed
WO-2014138907-A1 SUBSTITUTED AROMATIC COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, LIVER FIBROSIS, SKIN FIBROSIS AND CARDIAC FIBROSIS PROMETIC BIOSCIENCES INC. (CA) 2014-09-18 WO disclosed
EP-2632452-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER ProMetic BioSciences Inc. (CA) 2013-09-04 EP disclosed
US-20130217645-A1 Compounds and Compositions for the Treatment of Cancer PROMETIC BIOSCIENCES INC. (CA) 2013-08-22 US disclosed
WO-2012097427-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER PROMETIC BIOSCIENCES INC. (CA) 2012-07-26 WO disclosed
WO-2010127440-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF PROMETIC BIOSCIENCES INC. (CA) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210085626-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION COL1A1, CCNH, COL2A1 KDM4E 1096/4885ALDH1A1 129/4885PKM 2210/4885
US-20130217645-A1 Compounds and Compositions for the Treatment of Cancer DCK, TOP2B, TOP2A KDM4E 460/4885ALDH1A1 467/4885PKM 61/4885
US-20200237693-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS ADIPOR1, ADIPOR2, FN1 KDM4E 1479/4885ALDH1A1 1129/4885PKM 4187/4885
US-10391073-B2 Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration CCNH, COL1A1, COL2A1 KDM4E 1142/4885ALDH1A1 165/4885PKM 2383/4885
US-10815183-B2 Substituted aromatic compounds and pharmaceutical uses thereof TYR, PAH, REN KDM4E 1702/4885ALDH1A1 190/4885PKM 681/4885
US-20210002202-A1 Substituted Aromatic Compounds and Pharmaceutical Uses Thereof TYR, PAH, REN KDM4E 1702/4885ALDH1A1 190/4885PKM 681/4885
US-10869849-B2 Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration COL1A1, CCNH, COL2A1 KDM4E 1096/4885ALDH1A1 129/4885PKM 2210/4885
US-10450258-B2 Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis PAH, HRH3, CFH KDM4E 1111/4885ALDH1A1 402/4885PKM 3798/4885
US-20200078324-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION COL1A1, COL2A1, CCNH KDM4E 1136/4885ALDH1A1 139/4885PKM 2153/4885
US-11185521-B2 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis ADIPOR1, ADIPOR2, FN1 KDM4E 1479/4885ALDH1A1 1129/4885PKM 4187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.